Home
Learn More
Search Archives
Business Wire News
Business Wire Services
July 8, 2008
 
Industry Categories  
News by Country  
News by MSA  
Todays News  
Browse by Day  
PR Trackbacks™  
ViewNews™  
RSS  
 
EON: Enhanced Online News. Powerful technology and tools to help optimize your news content and enhance online visibility for major search engines.
A key component to your social networking and viral marketing strategy. In partnership with industry leader PRWeb.
 
All Press Releases for April 28, 2008 Subscribe to this News Feed      
 

Olympus Now Offers Complete Thyroid Panel for AU3000i® Immunoassay System

CENTER VALLEY, Pa. (Business Wire EON) April 28, 2008 -- With the introduction of the companys T-Uptake assay, Olympus now offers a complete thyroid panel for use with its AU3000i® immunoassay system, including TSH, T4, fT4, T3, fT3 and T-Uptake assays.

Screening of thyroid function is often indicated in persons with signs or symptoms of hypothyroidism, subclinical hypothyroidism, diabetes mellitus or hyperthyroidism, along with those who have had previous thyroid surgery or neck irradiation, the elderly, and others. It has been reported that about five percent of the U.S. adult population has thyroid disease or is taking thyroid medication.1,2 Consequences of untreated hyperthyroidism include atrial fibrillation, congestive heart failure, osteoporosis, and neuropsychiatric disorders. Hypothyroidism can cause symptoms that reduce the functional status and quality of life, such as depression or weight gain.

News Image The T-uptake assay measures the saturation of thyroid hormone binding capacities in a patient specimen. For diagnostic purposes the Olympus T-Uptake results should be used in conjunction with an Olympus Total T4 determination to yield the FTI. On-board stability for thyroid assays is 28-days and turnaround time is 28-minutes to first result. AU3000i reagents feature 2D barcodes for secure and convenient on-board reagent management. The AU3000i system has throughput up to 240 tests per hour, random access processing, magnetic particle capture and chemiluminescent detection.

For additional information about Olympus assays visit www.olympusamerica.com or contact Lorraine Damico, Olympus America Inc.; phone: 484-896-5463; email: lorraine.damico@olympus.com.

About Olympus Diagnostic Systems

Olympus Diagnostic Systems provides innovative solutions that meet the high productivity demands of hospitals, integrated healthcare delivery networks, reference labs, blood banks and pharmaceutical labs. Olympus offers the broadest standardized line of random access chemistry-immuno analyzers, along with lab automation systems, blood bank analyzers and reagents. Olympus solutions save laboratories time, maximize productivity, and deliver fast, reliable results.

About Olympus

Olympus is a precision technology leader, creating innovative opto-digital solutions in healthcare, life science and consumer electronics products. Olympus works collaboratively with its customers and its affiliates worldwide to leverage R&D investment in precision technology and manufacturing processes across diverse business lines. These include:

· Gastrointestinal endoscopes, accessories, and minimally invasive surgical products;

· Advanced clinical and research microscopes;

· Lab automation systems, chemistry-immuno and blood bank analyzers and reagents;

· Digital cameras and voice recorders.

Olympus serves healthcare and commercial laboratory markets with integrated product solutions and financial, educational and consulting services that help customers to efficiently, reliably and more easily achieve exceptional results. Olympus develops breakthrough technologies with revolutionary product design and functionality for the consumer and professional photography markets, and also is the leader in gastrointestinal endoscopy and clinical and educational microscopes. For more information, visit www.olympusamerica.com.

1. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002;87:489-99. [PMID: 11836274]

2. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000;160:526-34. [PMID: 10695693]

Post Comment:
Trackback URL: http://eon.businesswire.com/pingpr.php/SW5zZS1QaWdnLVNpbmctSG9yci1GYWx1LVplcm8=

Technorati Tags

Bookmark -  Del.icio.us | Digg | Furl It | Spurl | RawSugar | Simpy | Shadows | Blink It | My Web



OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
Email this story to a colleague
CONTACT INFORMATION

Edge Communications Inc.
R. Vincent Park, 914-684-0959
vincent@edge-comm.net

ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files by creating a Smart News Release at Business Wire.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases, please contact the company listed in the press release (see "Contact Information" in the right hand navigation panel). Please do not contact Business Wire or PRWeb®, as we will be unable to assist you with your inquiry.

Business Wire and PRWeb® disclaim responsibility for all content contained in these releases. Our complete disclaimer appears here.
 

About Us   |   Contact Us   |   Privacy Statement   |   Terms of Use (Updated)   |   © Business Wire 2006